Original Research Article Hepatitis B in Pregnancy: Knowledge, Access to Screening and Vaccination in a Low-Resource Setting, Cameroon.

7 ABSTRACT

Background: Hepatitis B virus infection (HBV) is a global public health problem with a high
burden in Sub-Saharan Africa. This burden is more felt in the paediatric population, mother
to child transmission (MTCT) being a major mode of infection. This study sought to assess
the knowledge of pregnant women on HBV and their access to screening and vaccination.

Methods: A cross-sectional study was carried out in the South West Region, Cameroon from 13 15th January to the 15th April, 2018 involving third trimester pregnant women attending 14 antenatal care (ANC) and those in the post-partum period admitted at the maternity wards of 15 some hospitals. Data was collected using a structured questionnaire and analyzed using SPSS 16 version 23. Knowledge was evaluated using a series of twelve questions. Vaccination status 17 was determined from vaccination cards and ANC registers.

Results: Of the 349 women studied, 31.8% were knowledgeable with scores of $\geq 6/12$. High educational level and occupation as a health worker were associated with good knowledge. Ninety (90.0%) had been screened for hepatitis B surface antigen (HBsAg) during pregnancy while 14.6% had been vaccinated. Determinants of vaccination were monthly income >60.000FCFA (OR: 5.7 CI: 1.6-19.9), urban residence (OR: 4.0 CI: 1.1-15.0) and regional level of ANC health facility (OR: 12.4 CI: 2.0-76.4).

24 **Conclusion:** Only about three in ten women is knowledgeable on HBV infection. Nine in ten 25 women are screened during pregnancy but only one in ten is vaccinated. We recommend that health education on HBV should be provided to pregnant women especially during antenatal 26 27 visits and that Preventive measures be re-enforced in South West Region.

28 Key words: Hepatitis B, Pregnancy, Prevalence, Determinants, Access, screening, 29 vaccination, Cameroon.

30

31

1. INTRODUCTION

Infection with Hepatitis B virus (HBV) is a major public health problem worldwide. Burdens of 32 33 the disease are mainly in WHO Western Pacific Region and WHO African Region where 6.2% 34 and 6.1% of the adult population is infected respectively [1]. Approximately 2 billion persons are 35 infected worldwide of which 240 million are chronic carriers of hepatitis B virus (HBV) [2].million are chronic carriers of hepatitis B virus (HBV) [2]. It is an important cause of 36 37 morbidity and mortality and approximately 800.000 infected persons die yearly of complications 38 of chronic hepatitis mainly liver cirrhosis and hepatocellular carcinoma (HCC) [2]. Sub-Saharan Africa is described as an area of high endemicity with an average prevalence above 8% [1,3]. 39 40 Few studies in Cameroon have evaluated the prevalence of HBV in different sub-populations reported as;11.9%, 19.9% and 7.7% in the general population, among children, and among 41 42 pregnant women respectively [4-6]. A more recent study at Buea health district showed a 43 prevalence of 9.7% in pregnant women [7]. These results place Cameroon at a high endemicity 44 for HBV infection (> 8% prevalence) and reveal that the disease burden in Cameroon is in the 45 pediatric population [1,5,8].

46 Mother-to-child-transmission (MTCT) is a major mode of HBV transmission worldwide, which 47 is problematic since around 90% of infected infants progress to chronic hepatitis B. This risk is 48 much higher than from horizontal transmission where the rate of chronicity is 30–50% when

infected before 6 years of age and <5% when infected in adulthood [1,9,10]. Perinatal 49 50 transmission being one of the commonest route of transmission, prevention of MTCT is therefore an essential step in reducing the burden of disease [11,12]. For this reason, routine screening of 51 all pregnant women for hepatitis B surface antigen in each pregnancy, introduction of hepatitis B 52 53 vaccine into the expanded program on immunization (adopted in 2005 in Cameroon) as well as 54 neonatal HBV immunoprophylaxis at birth and vaccination of pregnant women at high risk of 55 HBV is recommended [13–16]..Despite all these measures put in place, the prevalence of 56 hepatitis B in Cameroon as a whole, and in Cameroonian pregnant women remains high with a 57 prevalence of 7.7% in 2013 similar to 7.85% in a study done on samples collected ten years 58 earlier [4,17].

Hepatitis B vaccine is the most effective measure for preventing HBV infection. After receiving all three doses, it provides a greater than 90% protection when received before being exposed[1,20]. This vaccine is not contraindicated in pregnancy and is safe both for the mother and fetus when administered at any of the three trimesters of gestation [21,22]. A meta-analytic study in Iranian pregnant women, 2017 estimated the HBV vaccination coverage at 9.8% [23]. In China coverage was estimated at 33% in pregnant women [24].

65 Several studies have assessed the prevalence of hepatitis B in pregnancy as well as the risk 66 factors in Cameroon [4,7,25–27]. Hepatitis B vaccination in pregnancy is not one of the 67 recommended vaccines during antenatal care (ANC) in Cameroon. However, it is fast becoming a standard of care in some health institutions because of its proven efficacy in the prevention of 68 69 MTCT of hepatitis B. Despite this proven safety and protective effect of the vaccine, there is a 70 paucity of data about the vaccination coverage in pregnant women in Cameroon. This study 71 sought to assess the knowledge of pregnant women on HBV and their access to screening and 72 vaccination.

73

2. MATERIALS AND METHODS

74 2.1 Study Design, Study Setting and Enrollment of Participants

This cross-sectional study was conducted at the antenatal clinics of three facilities in the southwest region (Buea, Limbe, Kumba) from 15th January to the 15th April, 2018. Two centres were selected from the secondary and one in the primary level of healthcare based on their high antenatal care client turnout. The study sites were the District Hospital Kumba (primary); the Buea and Limbe Regional Hospitals (secondary).

The study population included pregnant women in the third trimester attending antenatal clinics and women in the postpartum period admitted at the maternity ward in each of the selected centres. These women were informed about the study and requested to sign a written consent if the understood goals, procedures and accepted to participate in the study. Women in the first and second trimester and those who had never attended antenatal care for the ongoing pregnancy were excluded.

2.1 Sample Size Calculation and Sampling

The minimum sample size was calculated using the LORENZ formula [28]. The HBV prevalence used was 20.4% reported by Ducancelle et al, 2013 [26]. A minimum sample size of 271 was obtained with a 95% confidence and 5% accuracy and considering a 10% nonrespondent rate. This sample size was then divided into the three hospitals according to their antenatal care turnout (BRH= 50 ANC clients/month giving a sample of 76 women; LRH= 60 ANC clients/month giving a sample of 90 women; DHK= 70 ANC clients/month giving a sample of 105 women). The study participants were chosen by convenience sampling.

94

95 **2.2 Data Collection**

97 A structured interviewer-administered questionnaire was used to collect data for both literate and 98 illiterate women in the language they best understood. The questionnaire contained questions 99 about socio-demographic characteristics, the knowledge of pregnant women about Hepatitis B 100 virus infection, their access to screening and vaccination was evaluated by a questionnaire based 101 cross-sectional study. Prior to the use of the questionnaire in study participants, the questionnaire 102 was pretested in 30 pregnant women with the aim of revising poorly structured questions, 103 estimate the average time required to fill the questionnaire and thus validate the use of the 104 questionnaire in our context. Information retrieved from pre-test group was not included in the 105 final analysis. After data collection, the data were entered into CS Pro and then exported to SPSS 106 version 23 for analysis.

107

108 **2.3 Data Analysis**

109 Knowledge was assessed by computing the number of correct responses to 12general knowledge 110 questions on Hepatis B and scored. For each correct answer, a score of one (1) was allocated, 111 while the score of zero (0) was allocated for no answer and for incorrect answers. Scores were 112 stratified into four levels based on Essi and Njoya's 2013 guide on assessment of knowledge in 113 KAP studies (Poor knowledge was considered for respondents with a total score of <3 marks(less 114 than 25% right answers); insufficient knowledge for scores ranging from 3 to5 (25 to 49% of 115 right answers), average knowledge for scores ranging from 6 and 8(50 to 69% of right answers) 116 and adequate knowledge for scores >8 (>70% of right answers) [29]. The vaccination status was 117 based on the vaccination card and ANC registers, in the absence of which the participant's recall 118 was used. All women who had a documentation of administration of at least a dose of hepatitis B 119 Vaccine were considered "vaccinated"; those who had received at least three doses of the vaccine were considered "completely vaccinated" while those who had not completed their vaccination 120

schedule were considered "incompletely vaccinated". Participants who had never received a dose of Hepatitis B vaccine were considered not vaccinated. The screening status was based on the documentation of HBsAg testing during the previous ANC sessions for the ongoing pregnancy.

Data was analysed with the Statistical Package for Social Sciences (SPSS) software version 23; frequency tables were created for proportions, Chi-square test for associations between categorical variables and one-way analysis of variance (ANOVA) for comparison of means between groups. Significant variables from cross tabulation between knowledge, screening vaccination status and sociodemographic variables were inserted into a binary logistic regression model. A p-value of <0.05 was considered statistically significant.

130 **3. RESULTS**

131 Out of a total of 353 potential participants who were approached for the study, 349 women were 132 recruited. Of these, 93 (26.6%) and 114 (32.7%) were enrolled at the Buea and Limbe Regional 133 Hospitals respectively (secondary centres); while 142 (40.7%) were enrolled at the District 134 Hospital Kumba (Primary centre). Four potential participants did not consent for personal reasons, giving a response rate of 98.9%. The ages of the participants ranged from 16 to 43 years 135 136 with a mean age of 27.35 ± 5.18 years in the general population. Majority were married or 137 cohabiting 234 (67%) while 115 (33%) were single. More than half 55 (58.5%) had <138 60000FCFA as monthly income. The study included 191 (54.7%) pregnant women and 158 139 (45.3%) women in the post-partum period. All pregnant participants were in the third trimester 140 with gestational ages (weeks) ranging from 28 to 41weeks and a mean of 32.2 ± 4.1 weeks. 141 Significant differences between participants in the different health facilities were found in age, 142 residence and gravidity. Table 1summaries the socio-demographic and obstetric characteristics of 143 the respondents.

145 Table 1. Socio-demographic characteristics of participants in the various centres

146

Variables	BR	Η		LRH	I	OHK	ΤΟΤΑ	A L	p-value
-	n	%	n	%	n	%	n	%	р (шис
Age									
<20	7	7.5	4	3.5	7	4.9	18	5.2	
20 < 25	28	28.6	27	23.7	36	25.4	91	26.1	
25 < 30	35	37.6	39	34.2	48	33.8	122	35.0	
30 < 35	21	22.6	37	32.4	38	26.7	96	27.5	0.004
>35	2	2.2	7	6.1	13	9.2	22	6.3	
Total	93	100	114	100	142	100	349	100	
Residence									
Urban	62	66.7	78	68.4	61	43.0	201	57.6	
Rural	31	33.3	36	31.6	81	57.0	148	42.4	0.000
Total	93	100	114	100	142	100	349	100	
Marital status									
Single	35	37.6	29	25.4	51	35.9	115	33.0	
Married	58	62.4	85	74.6	91	64.1	234	67.0	0.111
Total	93	100	114	100	142	100	349	100	
Income level									
<60.000fcfa	11	45.8	21	44.7	7	30.4	39	41.5	
>60.000fcfa	13	54.2	26	55.3	16	69.6	55	58.5	0.463
Total	24	100	47	100	23	100	94	100	
Gravidity									
1	47	50.5	38	33.3	39	27.5	124	35.5	
2-4	42	45.2	62	54.3	88	62.0	192	55.0	
≥5	4	4.3	14	12.2	15	10.6	33	9.5	0.004
Total	93	100	114	100	142	100	349	100	

147

148 On the assessment of knowledge, 195 (55.9%) of participants had a poor knowledge about HBV

149 infection, MTCT of HBV and HBV vaccination with knowledge scores <3. Only 74(21.2%) of

- 150 participants had good knowledge (knowledge score ≥ 8). Table 2 summarizes the knowledge of
- 151 study participants on Hepatitis B.
- 152

153 Table 2. Knowledge, screening and vaccination status of the participants.

154

Variables	Frequency (n= 349)	Percentage (%)	
Knowledge			
Good (score ≥ 8)	74	21.2	
Average (score 6-7)	37	10.6	
Insufficient (score 3-5)	43	12.3	
Poor (score <3)	195	55.9	
Previously screened			
Yes	314	90.0	
No	35	10.0	
Previously Vaccinated*			
Yes			
Completed (3 doses)	9	10.9	
Incomplete	38	1.1	
respecting schedule	4	10.9	
Incomplete not			
respecting schedule	51	14.6	
Total			
No	298	85.4	

155 *Vaccination status was based on participant's recall (3.9%) and vaccination cards (96.1%).

Knowledge about HBV was obtained from various sources; among all respondents, common
sources included counseling sessions (79.5%), discussions with relatives and friends (27.3%) and
the media (16.9%).

As shown in Table 2, 314 (90.0%) respondents had previously been screened for HBV infection during the ongoing pregnancy, and 51 (14.6%) had received at least one dose of hepatitis B vaccine. Only 9 (2.6%) were completely vaccinated. Thirty-eight (10.9%) were incompletely vaccinated but were following their normal vaccination schedule while 4 (1.1%) were

163 incompletely vaccinated and had missed their subsequent doses by more than two years. An 164 evaluation of associations between knowledge, previous screening and vaccination with 165 sociodemographic variables was done using cross tabulation and significant variables were 166 entered into a binary logistic regression model (Tables3 to 6).

Following a univariate analysis, health workers (OR: 0.9 CI: 0.9-1.0), respondents attending ANC in a regional hospital (OR: 3.4 CI: 3.0- 5.4) and respondents with more than primary level of education (OR: 0.1 CI: 0.0- 0.4) were more likely to have good knowledge p-values = 0.002, 0.000 and 0.000 respectively (Table 3). However, on multivariate analysis none of the factors were found to be predictors of good knowledge (Table 4). The tables 3 to 6 show predictors of good knowledge, screening and vaccination in the respondents.

173

174 Table 3. Factors associated with good knowledge on Hepatitis B.

Variables	Knowledge level		Odds ratio	Confidence p-value interval	
	Good	Not good			
Age					
<35	67(20.5%)	260(79.5%)	0.6	0.2-1.4	0.277
>35	7(31.8%)	15(68.2%)			
Occupation					
Health worker	4(100%)	0(0.0%)	0.9	0.9-1.0	0.002
Not health worker	70(20.3%)	275(79.7%)			
Level of Education					
\leq Primary	2(3.6%)	54(96.4%)	0.1	0.0-0.4	0.000
> Primary	72(24.6%)	221(75.4%)			
ANC hospital					
Secondary	47(33.3%)	94(66.6%)	3.4	2.0- 5.7	0.000
Primary	27(13.0%)	181(87.0%)			

175

176

177

179 Table 4. Predictors of good level of knowledge on Hepatitis B.

Variables	Good knowledge	AOR(Confidence Interval)	A p-value
Age			
<35	67(20.5%)	0.3(0.6-1.4)	0.254
>35	7(31.8%)		
Occupation			
Health worker	4(100%)	0.3(0.0-2.1)	0.999
Not health worker	70(20.3%)		
Level of education			
\leq Primary	2(3.6%)	0.3(0.03-2.2)	0.218
>primary	72(24.6%)		
ANC hospital			
Regional	47(33.3%)	2.5(0.8-8.0)	0.113
Peripheral	27(13.0%)		

182 Table 5. Predictors of Screening for Hepatitis B.

Variables	Previous screening (yes)	AOR (Confidence Interval)	A p-value
Age	-		
<35	279(90.3%)	0.5(0.06-5.0)	0.577
>35	20(90.9)	1	
Occupation			
≤60.000FCFA	247(89.8%)	1	
>60.000FCFA	70(94.6%)	1.0(0.2-5.7)	0.961
Level of education			
\leq Primary	48(85.7%)	0.5(0.1-2.4)	0.376
>primary	269(91.8%)	1	
ANC hospital			
Regional	136(96.5%)	5.6(1.1-28.4)	0.036
Primary	181(87.0%)	1	

192 Table 6. Predictors of HBV vaccination	192	Table 6.	Predictors	of HBV	vaccination.
---	-----	----------	------------	--------	--------------

193

Variable	N (%)	AOR (95% CI)	p- value
Knowledge			
Good knowledge	25(32.5)	2.6(0.8-9.1)	0.124
Poor knowledge	52(67.5)	1	
ANC health facility			
Regional hosp.	48(62.3)	12.4(2.0-76.4)	0.007
Primary.	29(37.7)	1	
State of client			
Pregnant	49(63.6)	2.4(0.5-11.5)	0.261
Post-partum	28(36.4)	1	
Residence			
Urban	45(58.4)	4.0(1.1-15.0)	0.037
Rural	32(41.6)	1	
Monthly income			
>60000	34(44.2)	5.7(1.6-19.9)	0.007
<60000	43(55.8)	1	

194

Pregnant women attending ANC at the regional hospitals were more likely to have been screened during the ongoing pregnancy (OR: 5.6, CI: 1.1-28.4, p= 0.036) and vaccinated than their counterparts (AOR 12.4(2.0-76.4) p= 0.007). Furthermore, those living in urban areas (p= 0.037) and those with a monthly income of greater than 60.000FCFA (p= 0.007) were more likely to have been vaccinated. However, a good knowledge on HBV infection was not significantly associated with HBV vaccination (Table 6).

201 4. DISCUSSION

Limiting Mother to child transmission of HBV infection has been identified as the main axis of care in order to envisage eradication of HBV infection worldwide. Screening asymptomatic people is an important instrument of disease detection, diagnosis and intervention but also a means of detecting candidates eligible for vaccination. Given that infected pregnant women stand the chance of transmitting the HBV infection to their newborn babies, we decided to conduct a cross-sectional study to determine what proportion of pregnant women attending ANC in Buea are knowledgeable, screened and/ or vaccinated during pregnancy to limit MTCT of HBV in the

southwest region. The information gathered from this piece of work will be used by the health
care providers in the region to scale up their current practices as concerns PMTCT of HBV
infection.

In the current study, the predominant age group of the respondents was 25<30years. This is similar to the results of Adeyemi *et al*, Nigeria 2013 who described a predominant age group of 26-35 years which is within the reproductive age bracket and this emphasizes the need for preventive measures in all women of childbearing age [30].

216 In our study, 31.8% of women had at least an average level of knowledge while up to 55.9% had 217 a poor knowledge on HBV infection. Good knowledge about HBV was found to be more likely 218 in women who attended antenatal care at the secondary level of healthcare, those with higher 219 levels of education and in health workers. The two latter may be due to their relatively higher 220 exposure to the healthcare services and information on HBV infection. Good level of knowledge 221 was associated with attending ANC in a higher health care level on the other hand could be due to 222 increase standards of care probably attributable to the greater number of specialists who have 223 been shown (Paulet al, Cameroon, 2017) to have a relatively higher level of knowledge on HBV 224 infection as opposed to other health care workers [31].

The results also reveal a high rate of HBsAg screening of pregnant women with a 90% screening rate. This result is similar to the findings of Walker et al in the USA; 2016 who had reported a screening rate of 98.5% [32]. It is however higher than the 8.5% reported by Adeyemi et al 2013, Nigeria. [30] This may be due to the relatively higher proportion of health practitioners in Cameroon who have incorporated HBsAg screening into the routine ANC as compared to those in Nigeria.

The vaccination rate of 14.6% for at least a dose of HBV vaccine was the highest reported nationwide [4, 25, 33]. This may be due to adoption of maternal HBV vaccination of non-

infected pregnant women in some of our study areas. The result is however lower than the 33%
reported by Chan et al in China, 2009 probably due to socio-economic differences between the
two settings [24].

Attending ANC at the secondary health care level was associated with higher rates of screening and vaccination probably due to increased standard of care as compared to the primary level. Living in an urban residence and having a higher monthly income were significantly associated with a higher vaccination rate probably related to the relatively easier accessibility to health care and also to information on the disease and its prevention via the media as supported by their relatively higher Knowledge on HBV earlier stated.

These findings may mean that vaccination is poor among pregnant women in our society and that more effort needs to be directed towards instituting guidelines and well-structured protocols for these services in adults.

245 **5. CONCLUSIONS**

Only one in five women had a good knowledge on HBV infection. However, high access to screening (90%) was high despite the low knowledge of women on HBV infection and its prevention. The HBV vaccine uptake rate in pregnant women was low at 14.6%. Higher vaccination rates were associated with antenatal care provided at the secondary health care level, good knowledge, screening, urban residence and higher monthly income.

We recommend that health education on HBV should be provided to pregnant women especially during antenatal visits and that preventive measures be re-enforced in our setting.

253 Limitations and Strengths of Study

The assessment of level of knowledge of the participants on hepatitis was not exhaustive using twelve questions but these questions were selected in such a way that they suited the study objectives and a scoring system ensure objectivity, reproducibility and reliability. Information on

the vaccination status was obtained from the participants so there was a risk of recall bias, however this was reduced by the fact that most of them (96 %) had vaccination cards. By selecting high volume centers providing both first and second levels of health care in the region, it permitted generalization of the findings which is a limitation of the study. Despite these limitations, this study addressed issues on Hepatitis B in pregnancy in a country where routine screening and vaccination have not been instituted as a national policy

263 **Declarations**:

264 Ethics Approval and Consent to Participate

Ethical clearance was obtained from the Faculty of Health Sciences Institutional Review Board of the University of Buea (N^O 2018/ 128/ UB/ SG/IRB/ FHS) and administrative authorization from the Regional Delegation of Public Health for the South West Region of Cameroon. Participants had the study protocol carefully explained to them and participation was voluntary. Written informed consent was obtained from all participants. All procedures were standard involving minimum risks.

271 Consent for publication

272 Not applicable

273 Availability of data and materials

The data sets supporting conclusion of this study are available from the corresponding author upon reasonable request.

276

277 List of abbreviations;

ANC: Antenatal care; CI: Confidence interval; HBsAg: Hepatitis B surface antigen; HBV:

Hepatitis B virus; MTCT: Mother to Child Transmission; WHO: World Health Organization.

280

281	
282	References
283	1.World Health Organization. WHO hepatitis B. Geneva: WHO; 2017. Available from:
284	http://www.who.int/mediacentre/factsheets/fs204/en/.[Accessed 28 Oct 2017]
285	2. Lavanchy D, Kane M. Global Epidemiology of Hepatitis B Virus Infection [Internet].
286	2016. p. 187-203. Availablefrom: http://link.springer.com/10.1007/978-3-319-22330-8_9. [
287	Accessed 2017 Nov 4]
288	3. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B
289	virus burden in developing countries. World J Gastroenterol. 2015;21(42):11941-53. Available
290	from: http://www.wjgnet.com/esps/helpdesk.aspx / DOI: 10.3748/wjg.v21.i42.11941. [Accessed
291	15 Nov 2017]
292	4. Fomulu NJ, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence,
293	correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is
294	perinatal transmission of HBV neglected in Cameroon? BMC Pregnancy Childbirth.
295	2013;13(1):158.
296	5. Chiaramonte M, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, Kaptue L, et al.
297	Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J
298	Med Virol. 1991;33(2):95–9.
299	6. Infectious Diseases of Cameroon: GIDEON Informatics, Google Books [Internet].
300	Cameroon: 2017 edition. Available from: https://www.gideononline.com/ebooks/disease.
301	Accessed2017 Nov 5]
302	7. Frambo AAB, Atashili J, Fon PN, Ndumbe PM. Prevalence of HBsAg and knowledge
303	about hepatitis B in pregnancy in the Buea Health District, Cameroon: a cross-sectional study.
304	BMC Res Notes. 2014;7(1):394.
305	8. Ndumbe PM, Njie TK. Hepatitis A and B infections in yaoundé, Cameroon. Res Virol.
306	1989; 140:253–61.
307	9. Gambarin-Gelwan M. Hepatitis B in Pregnancy. Clin Liver Dis. 2007;11(4):945–63.
308	10.Lai CL, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. The Lancet. 2003
309	;362(9401):2089–94.
310	11. Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, Poustchi H. Hepatitis B virus
311	infection during pregnancy: transmission and prevention. Middle East J Dig Dis. 2011;3(2):92.
312	12. Han Z, Yin Y, Zhang Y, Ehrhardt S, Thio CL, Nelson KE, et al. Knowledge of and
313	attitudes towards hepatitis B and its transmission from mother to child among pregnant women in

314 Guangdong Province, China. PLoS ONE [. 2017 2;12(6). Available from:
315 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5456270/.[Accessed 2018 Jan 14]

316 13. Ayoub WS, Cohen E. Hepatitis B management in the pregnant patient: an update. J Clin
317 TranslHepatol. 2016;4(3):241.

14. UNICEF. Cameroon: WHO and UNICEF estimates of immunization coverage: 2016
 revision. UNICEF; 2016. Available from: https://data.unicef.org/wp content/uploads/country_profiles/Cameroon/immunization_country_profiles/immunization_cmr.
 pdf

15. Expanded programme on immunization. Global Advisory Group--Part I. Releve
 Epidemiol Hebd. 1992;67(3):11–5.

16. Kane MA. Global status of hepatitis B immunisation. Lancet Lond Engl. 1996
14;348(9029):696.

32617. Kfutwah AKW, Tejiokem MC, Njouom R.A low proportion of HBeAg among HBsAg-327positive pregnant women with known HIV status could suggest low perinatal transmission of328HBVinCameroonVirologyJournalAvailablefrom:329https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-9-62. [Accessed 2017 Nov 13]

18. Nelson NP, Jamieson DJ, Murphy TV. Prevention of Perinatal Hepatitis B Virus
Transmission. J Pediatr Infect Dis Soc. 2014 Sep;3 Suppl 1:S7–12.

19. Knoema. Cameroun Taux de fertilité.Cameroon: 2017 Knoema.. Available from:
 https://knoema.fr//atlas/Cameroun/topics/Données-démographiques/Fertilité/Taux-de-fertilité.

334 [Accessed 2017 Nov 29]

Prevention. 335 20. Centers for Disease Control and HBV FAQs for Health 336 Professionals [Internet]. USA: CDC: 2016. Available from: 337 https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm. [Accessed 2017 Nov 4].

338 21. Centers for Disease Control and Prevention. Hepatitis B Vaccine Safety Vaccines

339 [Internet]. USA: CDC; 2015. Available from:

340 https://www.cdc.gov/vaccinesafety/vaccines/hepatitis-b-vaccine.html. [Accessed 2017 Nov 15]

22. Ayoola EA, Johnson AOK. Hepatitis B vaccine in pregnancy: Immunogenicity, safety
and transfer of antibodies to infants. Int J Gynecol Obstet. 1987 Aug 1;25(4):297–301.

23. Badfar G, Shohani M, Nasirkandy MP, Mansouri A, Abangah G, Rahmati S, et al.
Epidemiology of hepatitis B in pregnant Iranian women: a systematic review and meta-analysis.
Arch Virol. 2017; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMID:
29063378[Accessed 2017Nov 12]

24. Chan OK, Suen SSH, Lao TT-H, Leung VKT, Yeung SW, Leung TY. Determinants of
hepatitis B vaccine uptake among pregnant Chinese women in Hong Kong. Int J Gynecol Amp
Obstet. 106:232–5.

25. Noubiap JJN, Nansseu JRN, Ndoula ST, Bigna JJR, Jingi AM, Fokom-Domgue J.
Prevalence, infectivity and correlates of hepatitis B virus infection among pregnant women in a
rural district of the Far North Region of Cameroon. BMC Public Health [Internet]. 2015 ;15(1).
Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-015-1806-2.
[Accessed 2018 Apr 17].

26. Ducancelle A, Abgueguen P, Birguel J, Mansour W, Pivert A, Le Guillou-Guillemette H,
et al. High Endemicity and Low Molecular Diversity of Hepatitis B Virus Infections in Pregnant
Women in a Rural District of North Cameroon. PLOS ONE. 2013;8 (11). Available from:
<u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827216/</u>.[Accessed 2018 Apr 16].

27. PL026.Burden of Hepatitis B virus and the risk of vertical Transmission at the Penka
Michel Health District.Cameroon:PL026; Mar2017. Available from: http://www.masante-

361 cam.org/?q=node/273. [Accessed 2018 Apr 16].

28. Charan J, Biswas T. How to Calculate Sample Size for Different Study Designs in
Medical Research? Indian J Psychol Med. 2013;35(2):121–6.

364

29.Essi MJ, Njoya O. L'Enquête CAP (Connaissances, Attitudes, Pratiques) en
Recherche Médicale. Laboratoire de Recherche sur les Hépatites Virales et Communication
en Santé-FMSB.Health Sci. Di.2013; 14(2).

368 30. Adeyemi AB, Enabor OO, Ugwu IA, Bello FA, Olayemi OO. Knowledge of hepatitis B
virus infection, access to screening and vaccination among pregnant women in Ibadan, Nigeria. J
370 ObstetGynaecol J Inst ObstetGynaecol. 2013;33(2):155–9.

371 31. Paul T, Marie TP, Bechem E. Knowledge, attitude and practice of staff of 4 hospitals in
372 Yaoundé on the prevention of vertical transmission of hepatitis B. Pan Afr Med J. 2017
373 25;28(174). Available from: http://www.panafrican-med-journal.com/content/article/28/174/full/.
374 [Accessed 2018 Apr 20]

375 32. Walker TY, Smith EA, Fenlon N, Lazaroff JE, Dusek C, Fineis P, et al. Characteristics of
376 Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008377 2012. Public Health Rep. 2016;131(5):685–94.

378 33. Dionne-Odom J, Mbah R, Rembert NJ, Tancho S, Halle-Ekane GE, Enah C et al.
379 Hepatitis B, HIV, and Syphilis Seroprevalence in Pregnant Women and Blood Donors in
380 Cameroon: a cross-sectional study. Infectious Diseases in Obst and Gynecol Volume 2016.

- 381 Available from: http://dx.doi.org/10.1155/2016/4359401, Article ID 4359401. [Accessed 16
- 382 April 2018].